Full-Time

Workforce Planning Director

Updated on 8/1/2026

Vertex Pharmaceuticals

Vertex Pharmaceuticals

5,001-10,000 employees

Develops therapies for serious genetic diseases

Compensation Overview

$184.8k - $277.2k/yr

+ Annual bonus + Annual equity awards

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid

Hybrid work permits remote work up to two days per week; on-site designation requires five days per week on-site.

Category
Business & Strategy (1)
Required Skills
Data Analysis

Get referred to Vertex Pharmaceuticals

See people who can refer or advise you

Requirements
  • A bachelor's degree is required, plus an advanced degree in industrial-organizational psychology or a related field is strongly preferred.
  • Typically requires 10 years of experience in workforce planning, people analytics, strategic finance, workforce strategy, or a related field, including responsibility for an enterprise planning process at scale or the equivalent combination of education and experience.
  • Strong fluency in the financial mechanics of workforce planning, including total cost of labor, position management, and budget and long-range planning cycles.
  • Strong data and analytics skills, including statistical methods, scenario modeling, and the ability to connect workforce data to business dynamics, operating realities, and decisions.
  • Proven ability to partner across functions and business leadership to translate workforce insights into enterprise decisions.
  • Practical fluency using artificial intelligence tools to improve analytical work, automate repeatable tasks, synthesize complex information, quality-check outputs, and strengthen decision support.
  • Ability to translate workforce plans into staffing, organization, capacity, and labor-mix decisions with senior business leaders.
  • Planning exposure across labor categories, including employees, contingent workforce programs, vendor capacity, and early models for digital labor.
Responsibilities
  • Lead Vertex’s enterprise workforce planning cycle, including the long range plan, annual budget, position management, and monthly and quarterly forecasts.
  • Partner with Finance to develop planning assumptions, scenario models, affordability guardrails, and enterprise standards for executive decision-making.
  • Partner with HR business partners and Functional Finance to understand business context, pressure-test planning assumptions, and ensure workforce plans and processes reflect business conditions.
  • Plan across employees, contingent workers, vendor labor, and digital labor with consistent definitions, cost treatment, and governance.
  • Partner with Strategic Sourcing to align extended workforce planning with vendor strategy, contingent labor management, external capacity, and total cost of labor.
  • Translate artificial-intelligence-enabled work redesign, productivity assumptions, and digital labor models into workforce plans, capacity models, and planning scenarios.
  • Drive automation, standardization, and continuous improvement of workforce planning processes and reporting, incorporating artificial intelligence where applicable.
  • Partner with Talent Acquisition and HR business partners to connect workforce demand to hiring plans, recruiting capacity, pipeline priorities, internal mobility, build/buy/borrow decisions, and workforce risk management.
  • Partner with People Analytics to build dashboards, reporting, and insights that give leaders a consistent view of workforce trends and planning choices.
Desired Qualifications
  • An advanced degree in industrial-organizational psychology or a related field such as organizational behavior, labor economics, or applied statistics is strongly preferred.
  • Experience in the pharmaceutical, biotech, or science-driven industry is desirable.
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, with a focus on cystic fibrosis. It conducts extensive research and partners with other biotech firms to discover and develop new therapies, including ex vivo engineered cell treatments. Its products, such as ivacaftor, treat cystic fibrosis and other therapies undergo clinical testing to expand the pipeline. Revenue comes from selling approved drugs and from licensing and collaboration agreements. The company distinguishes itself through deep R&D investment, strategic partnerships, and a global reach aimed at addressing unmet medical needs. The overall goal is to bring effective new drugs to patients worldwide and improve outcomes and quality of life.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Get referred to Vertex Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Casgevy pediatric expansion broadens the treatable sickle cell and thalassemia market.
  • Late-stage assets like zimislecel, povetacicept, and inaxaplin add multiple launch catalysts.
  • JOURNAVX and kidney programs diversify revenue beyond cystic fibrosis.

What critics are saying

  • Casgevy uptake depends on reimbursement, safety, durability, and hospital capacity.
  • Zimislecel faces manufacturing delays and remains unproven in type 1 diabetes.
  • Revenue remains concentrated in a few products, leaving Vertex exposed to launch misses.

What makes Vertex Pharmaceuticals unique

  • Leads with cystic fibrosis franchise and approved CRISPR gene therapy Casgevy.
  • Runs a broad rare-disease pipeline spanning kidney, pain, and type 1 diabetes.
  • Combines internal R&D with partnerships and acquisitions, including CRISPR, Moderna, and Alpine.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

8%

2 year growth

8%
Massachusetts Business Alliance for Education
Jun 8th, 2026
MBAE honors rep. Alice Peisch and Vertex Pharmaceuticals for advancing educational opportunity.

MBAE honors rep. Alice Peisch and Vertex Pharmaceuticals for advancing educational opportunity. June 8, 2026 MBAE honored Representative Alice Hanlon Peisch and Vertex Pharmaceuticals at its annual Leadership in Education Awards luncheon for their outstanding contributions to expanding educational opportunity and advancing student success across Massachusetts. Representative Peisch received the MBAE Paul Reville Leadership in Education Award in recognition of more than two decades of public service and unwavering commitment to educational equity and opportunity. Since joining the Massachusetts House of Representatives in 2003, Peisch has been a leading advocate for educational excellence, equity, and accountability. As chair of the Joint Committee on Education from 2011 to 2023, she helped advance major reforms in school finance, special education, educator preparation, and literacy. She co-chaired the 2014 Foundation Budget Review Commission, whose recommendations helped shape the landmark Student Opportunity Act, and served on the National Assessment Governing Board, including as vice chair through 2024. The award was presented to Representative Peisch by Massachusetts Secretary of Education Stephen Zrike who along with Commissioner Pedro Martinez shared remarks during the event. The MBAE Jack Rennie Award for Business Impact in Education was presented to Vertex Pharmaceuticals and the Vertex Foundation for their commitment to advancing education, innovation, and community well-being. A leading corporate citizen in Massachusetts, Vertex partners with schools, nonprofits, and community organizations to expand access to STEAM (Science, Technology, Engineering, Arts, and Math) education, particularly for students from historically underrepresented and under-resourced communities. Through mentorship, hands-on learning experiences, and exposure to STEM careers, Vertex helps students envision pathways into science and innovation. MBAE's awards are named in honor of its co-founders, Paul Reville and Jack Rennie, who together led a five-year push for sweeping reform in the state's K-12 education system, resulting in the Massachusetts Education Reform Act of 1993. Reville later served as Massachusetts Secretary of Education. MBAE's annual awards luncheon celebrates the business community's commitment to excellence in public education.

Investing.com
Apr 13th, 2026
Argenx and Vertex Pharmaceuticals named BofA top biotech picks for 2026.

Argenx and Vertex Pharmaceuticals named BofA top biotech picks for 2026. Published 04/13/2026, 06:16 AM (C) Reuters. Investing.com - Bank of America has reaffirmed Argenx (NASDAQ:ARGX) and Vertex Pharmaceuticals (NASDAQ:VRTX) as its top large-cap biotech picks for 2026, with price targets of $1,013 and $598, respectively. For Argenx, BofA cited strong commercial performance of Vvygart in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, driven by expansion into earlier treatment lines and growing real-world experience. The firm highlighted upcoming phase 3 results for efgartigimod in myositis in the third quarter and empasiprubart in multifocal motor neuropathy in the fourth quarter as potential catalysts. For Vertex, BofA emphasized the strength of the cystic fibrosis franchise in providing cash flow to support pipeline expansion. The firm identified the rare kidney disease franchise as a key long-term growth driver, noting positive data for povetacicept in IgA nephropathy. Among commercial small- and mid-cap picks, BofA selected KalVista Pharmaceuticals (NASDAQ:KALV) with a $32 price target and Rhythm Pharmaceuticals (NASDAQ:RYTM) with a $149 price target. KalVista's Ekterly was approved in July 2025 as the first on-demand hereditary angioedema therapy, while Rhythm's Imcivree became the first approved therapy for acquired hypothalamic obesity in March. For pre-commercial small- and mid-cap stocks, BofA named Ocular Therapeutix (NASDAQ:OCUL) with a $27 price target and Bicara Therapeutics (NASDAQ:BCAX) with a $35 price target as top picks. Should you invest $2,000 in VRTX right now? ProPicks AI evaluates VRTX alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias - it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if VRTX is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?

National Today
Apr 11th, 2026
Fiduciary Alliance buys $2.2M stake in Vertex Pharmaceuticals

Fiduciary Alliance LLC purchased 4,828 shares of Vertex Pharmaceuticals during the fourth quarter, valued at approximately $2.19 million, according to a recent 13F filing with the Securities and Exchange Commission. The investment reflects confidence in the Boston-based biotechnology company, which specialises in developing treatments for serious diseases, particularly cystic fibrosis. Vertex's portfolio of CFTR modulators has transformed standards of care for many CF patients. Vertex's share price has risen over 20% in the past year as the company continues expanding its cystic fibrosis treatments and exploring new therapeutic areas. The investment signals institutional interest in Vertex's growth potential and drug pipeline.

GlobalData
Apr 8th, 2026
Halozyme and Vertex sign deal for Hypercon technology.

Halozyme and Vertex sign deal for Hypercon technology. Under the agreement, Vertex will make a $15m upfront payment to Halozyme and potential future milestone payments. Halozyme Therapeutics' subsidiary Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for the former's Hypercon technology. Vertex has licensed the technology for use in up to three drug targets, as part of the agreement. The Hypercon microparticle platform enables hyperconcentration of drugs and biologics, aiming to reduce injection volume and facilitate at-home administration for patients. Vertex will make an upfront payment of $15m to Halozyme, along with potential future milestone payments. Halozyme will also receive royalties on net sales of any products that are developed using the technology. Halozyme Therapeutics president and CEO Helen Torley said: "This collaboration with Vertex underscores the versatility and potential of its Hypercon technology to enable small volume, patient-delivered next generation biologics. "Vertex is a proven innovator with deep expertise, and we believe Hypercon can play an important role in supporting improved ease of patient access to targeted biologics that have the potential to advance innovation for patients with serious diseases." Halozyme's Enhanze drug delivery technology, based on the enzyme rHuPH20, supports the subcutaneous administration of injected drugs and fluids to lower treatment burden and enhance convenience. Enhanze has been involved in over one million patient lives through ten commercialised products across more than 100 countries, and is licensed to companies such as AbbVie, Eli Lilly, Pfizer, Roche, Takeda, and ViiV Healthcare. Halozyme has expanded its drug delivery portfolio to include Hypercon, as well as Surf Bio's polymer-based hyperconcentration technology, broadening the possibilities for subcutaneous biologics delivery. In January 2026, Takeda announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the latter's Enhanze drug delivery technology. Give your business an edge with its leading industry insights.

The Pharma Letter
Apr 8th, 2026
Halozyme inks license agreement with Vertex.

Halozyme inks license agreement with Vertex. 8 April 2026 San Diego, USA-based Halozyme Therapeutics (Nasdaq: HALO) late yesterday announced it has entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals (Nasdaq: VRTX). This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 17 November 2025 25 April 2025 14 September 2017 Company news directory. Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 8 April 2026 7 April 2026 Company spotlight. A clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases characterized by abnormal appetite and metabolic disorders. More features in pharmaceutical. 8 April 2026 7 April 2026